Grünenthal press release 2012

Brussels / Rome / Aachen, 20 November 2012. Pain Alliance Europe (PAE) representing chronic pain patients in Europe, Active Citizenship Network (ACN) and Grünenthal have entered into an official partnership on the development of European Pain Patient Pathways Recommendations. The projects will run until December 2014 and aims to create a greater awareness of chronic pain and to promote European policy-making for improved management of chronic pain.

Aachen, Germany, November 8th, 2012 – The Grünenthal Group and Amura Therapeutics LTD (Cambridge, UK) announced today that they have entered into a Collaboration Agreement. The focus of this collaboration is the development of protease inhibitors which play a key role in pain and inflammation, key focus areas in Grünenthal’s research-focused Strategic Business Unit Grünenthal Innovation.

Aachen, September 10, 2012 – In the first half of 2012 Grünenthal Group, an international pain therapy expert, reached revenues of €473 mn (vs. € 483 mn in H1 2011). Corrected by divested businesses, core business grew by 9 per cent in the first half of 2012.

Milan, August 29th, 2012 – Ask pain patients what they expect from their treatment and the answer is simple. “I want to sleep through the whole night” or “I want to be able to walk with my wife”. They want relief with minimal side effects to master a normal life. Therefore, people with chronic pain may also be attracted by treatments offering flexibility; a sense of control over their disease even when pain management is required for extended periods.

Milan, 28th August, 2012 - A recently published phase IIIb study, presented at the International Association for the Study of Pain (IASP^®) 14th World Congress on Pain in Milan, found that patients suffering from chronic low back pain (LBP) with and without a neuropathic pain component can benefit from tapentadol treatment.

Milan/Aachen, 27th August 2012. Chronic pain has a high prevalence world-wide. In Europe, 80 million people are suffering from chronic pain, which results in approximately 500 million sick days and accumulates costs of around 34 billion Euros.

Aachen, June 20, 2012 – The Grünenthal Group is one of the best employers in Europe. This was the finding reached by the Great Place to Work^® Institute, which included four of the Aachen-based pharmaceutical corporation’s locations in this year’s European list of top-ranking companies. With national successes in Spain, Belgium, the Netherlands and Ireland the Grünenthal Group ranks among Europe’s top 25 employers for the first time.

Aachen (Germany)/Panama City (Panama) – June 19, 2012: The Grünenthal Group today announced that it has entered into an exclusive agreement with Horizon Pharma, Inc. (NASDAQ:  HZNP), a biopharmaceutical company, for the commercialization of DUEXIS^® in Latin America.

Aachen, June 14th, 2012 - New chemical entities (NCE) in the areas of pain and inflammation as well as the formulation technology platform INTAC^® are at the core of Grünenthal’s presentation at BIO International Convention 2012.

New York, June 6, 2012 – The Grünenthal Group, a leader in pain therapeutics headquartered in Aachen, Germany, presented today at the Jefferies 2012 Global Healthcare Conference in New York. Grünenthal CEO Harald F. Stock, PhD., told at the meeting that the company expects to continue to expand its market share through both organic, focused growth in its pain medication portfolio and targeted acquisitions, particularly in Latin America in line with its transformational long-term strategy, Vision 2020.